Dr. Guy S. Strauss, D.O.
Internal Medicine (Internal Medicine Physician)
404 Nw Hall Of Fame Dr
Lake City, FL 32055
Who else practices at this address →
Columbia County is a federal mental health shortage area. About shortage areas
- Medicare participating
At a glance
- Medical school
- New York College of Osteo Medicine of New York Institute of Technology (1983)
- Years since graduation
- 43
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 561
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1983Medical school: New York College of Osteo Medicine of New York Institute of Technology
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
FL license OS4706 · SC license TL1019 -
Critical Care Medicine (Internal Medicine) Physician
FL license OS4706 · SC license TL1019
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Uf Health Shands Hospital Gainesville, FL
- HCA Florida North Florida Hospital Gainesville, FL
- HCA Florida Lake City Hospital Lake City, FL
Medical groups
- Southern Internal Medicine PLLC (4 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 561
- Services billed
- 11,642
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Insertion of needle into vein for collection of blood sample | 2,465 | 612 |
| Established patient office or other outpatient visit, 30-39 minutes | 1,660 | 572 |
| Blood test, basic group of blood chemicals (calcium, total) | 1,293 | 543 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 974 | 486 |
| Hemoglobin a1c level | 906 | 337 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 856 | 119 |
| Established patient office or other outpatient visit, 20-29 minutes | 746 | 364 |
| Established patient office or other outpatient visit, 40-54 minutes | 701 | 494 |
| Magnesium level | 626 | 284 |
| Manual urinalysis test with examination using microscope, automated | 599 | 468 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 11 companies reported 30 payments worth $775 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $268 |
|---|---|
| Novo Nordisk Inc | $102 |
| Novartis Pharmaceuticals Corporation | $87.99 |
| Pfizer Inc. | $76.93 |
| Lilly USA, LLC | $60.67 |
| AbbVie Inc. | $53.91 |
| Bayer HealthCare Pharmaceuticals Inc. | $35.99 |
| Vifor Pharma, Inc. | $29.84 |
| Food and Beverage | $585 |
|---|---|
| Travel and Lodging | $190 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Jan 22, 2025 | Travel and Lodging travel to Boston, MA · in-kind Company’s descriptionResearch Related Service | $109 |
| AstraZeneca Pharmaceuticals LP Feb 7, 2025 | Travel and Lodging travel to Boston, MA Company’s descriptionResearch Related Service | $48.88 |
| AstraZeneca Pharmaceuticals LP Feb 7, 2025 | Travel and Lodging travel to Boston, MA Company’s descriptionResearch Related Service | $32.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 16 industry-funded studies in 2025, from 6 companies. The companies reported $2,079,389 in research payments for these studies, mostly to the institutions running them.
- A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
ModernaTX, Inc. · Completed · NCT06602024 - A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age
ModernaTX, Inc. · Completed · NCT05127434 - A Phase IIb Randomized Double blind Placebo controlled and Open label Active Comparator Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Adults with Type 2 Diabetes Mellitus
AstraZeneca Pharmaceuticals LP - ISM2504007A--Clinical Evaluation of the i-STAT Crea, CG4+ and CG8+ Carridges using Neonatal Capillary Whole Blood Specimens with the i-STAT 1 Analyzer
Abbott Laboratories - A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate …
AstraZeneca Pharmaceuticals LP - A phase 3 study to evaluate the efficacy immunogenicity and safety of respiratory syncytial virus rsv prefusion f subunit vaccine in adults
Pfizer Inc. - A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes
ModernaTX, Inc. · Completed · NCT06033261 - A phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd …
AstraZeneca Pharmaceuticals LP - A phase 3 placebocontrolled doubleblinded randomized study to evaluate the efficacy safety and tolerability of a clostridioides difficile vaccine in adults 65 years of age and older
Pfizer Inc. - A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
Teva Pharmaceuticals USA, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.